Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials

Area of Science:

• Reproductive health
• Clinical trial methodology
• Pharmacoeconomics

Background:

• Clinical trials for contraceptives exhibit significant design variability, hindering direct comparisons of efficacy.
• Key design elements, such as menstrual cycle inclusion rules and pregnancy definitions, differ across studies.

Purpose of the Study:

• To highlight technical design variations in contraceptive trials that impede cross-trial comparisons.
• To inform healthcare providers and patients about factors influencing contraceptive efficacy data.

Main Methods:

• Analysis of common contraceptive trial design features, including menstrual cycle qualification rules.
• Examination of statistical methods like the Pearl Index and time-to-event analysis.
• Review of criteria for body mass index and "on-treatment" pregnancy definitions.

Main Results:

• Exclusion of menstrual cycles, due to factors like lack of intercourse, can inflate calculated failure rates.
• Variations in study length and cycle rules affect efficacy outcomes, particularly between hormonal and non-hormonal contraceptives.
• The US Food and Drug Administration's (FDA) 2019 Draft Guidance aims to standardize hormonal contraceptive trial designs.

Conclusions:

• Discrepancies in contraceptive trial methodologies complicate the assessment of relative product efficacy.
• Awareness of design nuances is essential for clinicians and patients when interpreting contraceptive trial data.
• Standardization efforts, like the FDA guidance, are needed to improve the reliability of contraceptive efficacy research.